Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07622914 · ClinicalTrials.gov registry record
The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer
A clinical trial, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- 59
- Enrollment target
NCT07622914: Recruiting study, sponsored by University of Oklahoma.
NCT07622914 is a clinical trial that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07622914 is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- 59 participants
- Enrollment target
Study Summary
Emerging data suggest consumption of dietary fiber before and during cancer treatment may improve prognosis for patients with head and neck cancer, in part via increased production of short chain fatty acids, systemic anti-inflammatory effects, and decreased risk of sarcopenia. Foods rich in dietary fiber are often low in calories and protein, thus are not typically targeted in current treatment paradigms that focus on countering the catabolic state associated with sarcopenia. This project entails an observational, mixed methods study to: observe dietary fiber intake in patients with head and neck cancer from time of diagnosis for six months; elucidate the relationship between dietary fiber intake, short chain fatty acids, inflammatory markers, and sarcopenia; and explore the feasibility of and patient perceptions regarding promoting dietary fiber as part of their treatment approaches.
Primary Outcome
Reported dietary fiber intake (grams per day) will be measured using the Diet History Questionnaire 3 (DHQ3) to provide a mean value consumed per day over 30 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2025-10-31 |
| Est. Completion | 2027-06-30 |
What NCT07622914 shows while recruiting
NCT07622914 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07622914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07622914 about?
NCT07622914 is a clinical study titled "The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer". Emerging data suggest consumption of dietary fiber before and during cancer treatment may improve prognosis for patients with head and neck cancer, in part via increased production of short chain fatty acids, systemic anti-inflammatory effects, and decreased risk of sarcopenia. Foods rich in dietary...
What is the current status of trial NCT07622914?
This trial is currently recruiting. The enrollment target is 59 participants. The study started on 2025-10-31. Estimated completion is 2027-06-30.
Who is sponsoring clinical trial NCT07622914?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI